C.Diff Treatment Completes Successful Clinical Trials

摘要

Second phase clinical trials of a treatment for Clostridium difficile Infection (CDI), discovered at the University of Strathclyde, have been successfully completed having met its targets of safety, efficacy and dose selection. The study, carried out in the US and Canada by Glasgow-based biopharmaceutical company MGB Biopharma, confirmed that the antibacterial treatment MGB-BP-3, has the potential to become the new gold standard, first-line treatment for CDI. Other compounds related to MGB-BP-3 are now to be investigated in a project led by Strathclyde for their potential to treat COVID-19. The success of MGB-BP-3 in the clinic is very encouraging for this new study.